In the BioHarmony Drug Report Database

"Preview" Icon

Valbenazine

Ingrezza (valbenazine) is a small molecule pharmaceutical. Valbenazine was first approved as Ingrezza on 2017-04-11. It is used to treat tardive dyskinesia in the USA. The pharmaceutical is active against synaptic vesicular amine transporter. Ingrezza’s patents are valid until 2040-08-10 (FDA).

 

Trade Name

 

Ingrezza
 

Common Name

 

valbenazine
 

ChEMBL ID

 

CHEMBL2364639
 

Indication

 

tardive dyskinesia
 

Drug Class

 

Image (chem structure or protein)

Valbenazine structure rendering